HIV-HBV coinfection among South African patients receiving antiretroviral therapy

Antiviral Therapy

Volumn 15, Issue 3 PART B, 2010, Pages 499-503

  Di Bisceglie, Adrian M ^a,b   Maskew, Mhairi ^c   Schulze, Doreen ^c   Reyneke, Anne ^c   McNamara, Lynne ^d   Firnhaber, Cindy ^c,d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d RIGHT TO CARE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS DNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; HEALTH SURVEY; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATION; MIXED INFECTION; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; SOUTH AFRICA; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TRANSMISSION; COMPLICATION; DRUG COMBINATION; GENETICS; HEPATITIS B VIRUS; HIV INFECTIONS; PREVALENCE; VIROLOGY;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA;

EID: 77953434881     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1494     Document Type: Review

References (21)

1. Botha JF, Ritchie MJJ, Dusheiko GM, Mouton HWK, Kew MC. Hepatitis B virus carrier state in Black children in Ovamboland: role of perinatal and horizontal transmission. Lancet 1984; 323:1210-1212.
2. Di Bisceglie AM, Kew MC, Dusheiko GM, et al. Prevalence of hepatitis B virus infection among Black children in Soweto. Br Med J (Clin Res Ed) 1986; 292:1440-1442.
3. Vardas E, Mathai M, Blaauw D, et al. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 1999; 58:111-115. (Pubitemid 29226851)
4. Burnett RJ, Ngobeni JM, Francois G, et al. Increased exposure to hepatitis B virus infection HIV-positive South African antenatal women. Int J STD AIDS 2007; 18:152-156.
5. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut 1996; 38 Suppl 2:S31-S36.
6. Kleinschmidt I, Pettifor AE, Morris N, MacPhail C, Rees H. Geographic distribution of human immunodeficiency virus in South Africa. Am J Trop Med Hyg 2007; 77:1163-1169.
7. Shisana O, Rehle T, Simbayi LC, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: a turning tide among teenagers? Cape Town: HSRC Press 2009.
8. Pettifor AE, Rees HV, Kleinschmidt I, et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 2005; 19:1525-1534.
9. Firnhaber C, Reyneke A, Schulze D, et al. The prevalence of hepatitis B coinfection in a South African urban government HIV clinic. S Afr Med J 2008; 98:541-544.
10. Lodenyo H, Schoub B, Ally R. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr Med J 2000; 77:13-15.
11. Mphahlele MJ, Lukhwareni A, Burnett R, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35:14-20.
12. Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South Africa ART program. Clin Infect Dis 2008; 47:1479-1485.
13. Hoffmann CJ, Charalambous S, Thio C, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
14. Selabe SG, Song E, Burnett RJ, Mphahlele MJ. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes. J Med Virol 2009; 81:996-1001.
15. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudine-resistance in therapy-niave hepatitis B virus (HBV) infected patients with and without HIV coinfection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007; 79:1650-1654.
16. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2006 revision. (Updated 3 February 2009. Accessed 12 October 2009). Available from http:// www.who.int/hiv/pub/guidelines/artadultguidelines.pdf
17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. October 2006. (Accessed 12 October 2009.) Available from http:// aidsinfo.nih.gov/guidelines/
18. Piroth L, Binquet C. Vernge M etal. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002; 36:681-686.
19. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36:869-875.
20. Firnhaber C, Viana R, Reyneke A, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV coinfection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009; 13:488-492.
21. Lukhwareni A, Burnett RJ, Selabe G, et al. Increase detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J Med Virol 2009; 81:406-412.